Promising new combination therapy for advanced kidney cancer
Combinations of tyrosine kinase inhibitors plus immunotherapy have improved treatment [...]
Pazopanib plus bevacizumab shows promise as a first-line treatment for kidney cancer
Results from a phase 2 study of pazopanib alternated with [...]
Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
Immunotherapy combinations versus TKIs for papillary renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the most common subtype [...]
Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
New treatment, zanzalintinib, for advanced kidney cancer
A recent clinical trial looked at a new anti-cancer medication [...]
Treatment of translocation kidney cancer
Translocation kidney cancer is a rare type of kidney cancer [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
